药明生物荣膺多项亚太生物工艺卓越奖项 彰显生物工艺、生产制造与数字化创新领军地位

今年所获殊荣进一步彰显了药明生物作为全球生物制药创新企业及跨国公司首选合作伙伴的领军地位。截至2025年，公司平台综合项目达945个，拥有全球规模最大的复杂生物药管线之一，其中近50%为双特异性 / 多特异性抗体与抗体药物偶联物（ADC）。公司持续通过创新技术平台拓展一体化服务能力，助力缩短研发周期、提升产品质量并实现规模化生产。2025年，公司推出行业领先的定点整合技术CHO细胞株开发平台WuXia™ TrueSite，实现单抗平均表达量超8.0克/升，且超过99%的克隆细胞株在传60代次后仍保持稳定的蛋白表达。公司还推出高剂量给药技术解决方案，包括高浓度制剂开发平台WuXiHigh™，可实现最高230mg/mL 的蛋白浓度，并将粘度降低达90%。

药明生物同时引领数字化创新，赋能生物药研发与生产变革，将数字技术深度融入研发、生产、运营及客户合作全流程，全面提速项目进展、提升产品质量，并强化与合作伙伴的透明协同。例如，通过电子批记录（EBR）等数字化生产解决方案，公司不仅提升了约40%的生产力，更确保了数据完整性和产品质量。通过使用高效资源计划系统则实现了约20%的效率提升。近期，药明生物还推出行业领先的数字孪生平台PatroLab™，优化工艺性能、降低工艺风险、缩短开发周期，确保稳定、高质量的生物药生产。

ABEA由生物制药领域专业咨询公司IMAPAC主办，旨在表彰在生物工艺、供应链、ADC开发及临床开发等领域展现杰出创新、严谨运营与行业领军地位的组织与个人。该奖项对生物制药从业者、企业与前沿技术所做出的卓越贡献给与认可，表彰引领行业未来的先锋领袖与标杆企业，持续激励生物制药领域不断创新发展。

This year's awards further validate WuXi Biologics' leading position as the partner of choice for biopharma innovators and multinational corporations worldwide. The company has 945 integrated projects on its platform, making it one of the world's largest portfolios of complex biologics. Among them, nearly 50% are bi- and multi-specific antibodies and ADCs. It continues to expand its integrated services through new technology solutions that accelerate timelines, improve product quality and ensure scalable manufacturing. In 2025, the company launched WuXia™ TrueSite, its industry-leading targeted integration-based CHO cell line platform, achieving average mAb titers over 8.0 g/L and outstanding expression stability through 60 generations. It has also advanced its high-dose delivery technologies into clinical and commercial use, including its high-throughput formulation development platform WuXiHigh™, which enables protein concentrations of up to 230mg/mL and achieves viscosity reduction by up to 90%.

Building on its innovative technology platforms, WuXi Biologics consistently leads the industry in manufacturing and bioprocessing excellence. The company has achieved a 100% success rate in PPQ campaigns. It has delivered more than 350 large‑scale batches (6,000 L – 16,000 L per batch) for global partners since 2017. The strong manufacturing track record is underpinned by WuXi Biologics' rigorous, global quality system. As of the end of 2025, the company had successfully passed 46 regulatory inspections, including 22 inspections conducted by the FDA and EMA. The company also holds an industry-leading record with a 100% pass rate for FDA Pre-License Inspection (PLI). Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network, with 136 facility license approvals and a 100% success in GMP inspections. Its world-class quality and compliance capabilities remain the cornerstone of clients' trust.

Presented by IMAPAC, the Asia-Pacific Biopharma Excellence Awards honor outstanding innovation, operational rigor, and industry leadership across bioprocessing, supply chain, ADC development, and clinical development. Recognizing the remarkable contributions of leading biopharma professionals, organizations, and technologies, the awards spotlight trailblazing leaders and trendsetters shaping the industry's future while inspiring innovation for tomorrow's biopharma landscape.